SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-21-012044
Filing Date
2021-06-10
Accepted
2021-06-10 17:17:47
Documents
13
Period of Report
2021-06-09
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tvtx-20210609.htm   iXBRL 8-K 42952
2 EX-3.1 ex31bylawamend06-09x21.htm EX-3.1 7133
  Complete submission text file 0001628280-21-012044.txt   199597

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20210609.xsd EX-101.SCH 1983
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tvtx-20210609_lab.xml EX-101.LAB 26305
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tvtx-20210609_pre.xml EX-101.PRE 13798
6 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20210609_htm.xml XML 11705
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 211008977
SIC: 2834 Pharmaceutical Preparations